04/05/2016 08:56:12 Cookie Policy +44 (0) 207 0700 961 Free Membership Login
Share Name Share Symbol Market Type Share ISIN Share Description
Aortech International LSE:AOR London Ordinary Share GB0033360586 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 22.50p 22.00p 23.00p 22.50p 22.50p 22.50p 0 07:53:27
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.8 -0.3 -7.7 - 1.09

Aortech Share Discussion Threads

Showing 3276 to 3299 of 3300 messages
Chat Pages: 132  131  130  129  128  127  126  125  124  123  122  121  Older
DateSubjectAuthorDiscuss
25/4/2016
13:29
Sorry - very early for humour!! I know the fall was caused by one decent sized seller before the tax year end who needed the loss but he did manage to sell quite a few and someone must have bought them! It has gone very quiet though
harrogate
25/4/2016
09:01
Sorry Harrogate - I was trying to be ironic! It is slightly interesting though.
semper vigilans
25/4/2016
08:45
It was only 10,000 shares that took them over 3% so not massive
harrogate
25/4/2016
08:42
Interesting that Standard Life would go over 3% with such a massive purchase. Can only be good news?
semper vigilans
15/3/2016
12:47
It would make total sense for Aortech to sell elasteon and keep the heart valve. Biomerics would be able to control its market and retain all the margin and be able to develop sales/ Product innovation from a position of financial strength. We would be able to concentrate on the heart valve J/Vent with $10mill+ in the bank. Happy days
spurious
15/3/2016
12:35
Interesting Spurious....? Aortech could be in their sights but what would they have to pay to own Elasteon and the next generation material poly super carbonate.. I think that is what it is.. I am sure there will be those to put me right. Elasteon and associated products should be worth $5-10M minimum surely. Heart valve... well I cannot see Biomerics going for that so maybe sell off Elasteon and keep the hear valve project in New Co? Great find...
gac141
15/3/2016
12:19
Hitachi Metals Ltd. said Thursday it will acquire two U.S. medical equipment components companies for $84 million in February, in a bid to strengthen its medical technology business. Hitachi Metals will make HTP-Meds LLC and Hi-Tech Machine and Fabrication LLC, both based in Rhode Island, wholly owned subsidiaries via its U.S. unit. HTP-Meds manufactures medical tubes used for catheters and dialysis, while Hi-Tech Machine and Fabrication makes molds for such tubes. Through the acquisitions, Hitachi Metals said it aims to expand its medical tubing business in North America and other markets. ==Kyodo This is all I could find in trying to work out what sort of a war chest Biomerics might have at its disposal Its 50% share in HTP Med sale would give Biomerics $21 million assuming both companies mentioned above were of equivalent size/value It could be more or less than this but represents a considerable sum for Biomerics to develop /expand its business Could Aortech be in its sights. It would appear to be an opportunistic moment for both companies Lets deal! Regards Sp
spurious
24/2/2016
17:10
Totally understandable when invested with a serial disappointer like Aor that we all can miss the positive changes taking place and as a result patience is not rewarded. I genuinely believe the changes taking place currently will have a major impact on the share price in the coming months or I would not still be invested Best regards SP
spurious
24/2/2016
16:45
Thanks for taking the time to go through that. It is funny how the mind works. I didn't even let those words register when I read the results. AOR has been so much about the words not being followed up in the P&L account that I don't even read them but just wait to see the numbers. That does suggest that there is finally some traction on licences and we may see this in the numbers. Thanks again.
harrogate
24/2/2016
14:22
Hi Harrogate You are right to challenge my enthusiasm and perhaps it owes more to an inability to hold my drink ! On a more sobering note here's what Aortech said in August 2015 re full year results " As reported in last year's Accounts, a licence with Biomerics LLC was concluded for the manufacture and distribution of AorTech's Elast-Eon(TM) materials. We expressed some disappointment in the progress of this licence in our 2014 Interim Results but I am now pleased to confirm that there has been progress on the contractual relationship between AorTech and Biomerics with an amendment to the original agreement concluded since the year end. This amended agreement incorporates several commercial changes including further capital expenditure by both companies. AorTech's capital expenditure commitment will be paid from future royalties. The further positive news on this agreement is the commitment of a long term supply of Elast-Eon(TM) to one of AorTech's major licensees together with further enquiries from other potential customers regarding receiving supplies of Elast-Eon(TM). Other Licensees I am pleased to report, as demonstrated in the growth of AorTech's revenue, the continued increase of royalties from existing licensees. The licensees who have achieved commercialisation are continuing to see increased sales which should in turn result in increased royalties to Aortech." At interims Aor said Conclusion " The business continues to make progress and our Manufacturing Licensee has a growing prospects list. We recently commissioned a detailed report from a world leading biomaterials expert to review the potential of AorTech's IP portfolio. The report is extremely positive in that the Elast-Eon(TM) family of materials continues to be the leading material for implantable medical devices. Your Board, in conjunction with the author of the report will be reviewing all of the recommendations contained therein. A range of opportunities have been identified which also includes the filing of additional patents to further strengthen AorTech's IP portfolio." Not so much detail but confirmation they are continuing to make progress and relationship is working well with Biomerics Perhaps something to do with fact Frank no longer there We can only be sure when we see the orders but I am hoping evidence may be close and I am more confident we will see a successful outcome to the heart valve proposed fund raise/flotation which I believe will be transformational regards SP
spurious
24/2/2016
08:10
Thanks for finding these things. One question - do we really have any evidence that Biomerics are "going great guns with elasteon"? We have had almost no news from AOR on licences or any signs of increasing royalties and while I think it is clear there can be a long time lag to actual revenue from signing there seems no evidence to support great progress in the core AOR business - it seems to be a punt on a legal case to provide more funding and thus more time and a hope that the heartvalve is both valuable IP and that the management here will be fair to AOR shareholders in the way that they attempt to extract value from it.
harrogate
23/2/2016
16:24
Hi George Interesting find indeed ! Particularly interesting where they say they will invest all the proceeds back into growing the business This can only be good for Aortech as... more resources /support should result in greater sales Why dont Biomerics who by all accounts are going great guns with elasteon enter into a bidding war with Foldax and buy us out Why not invest in the proposed heart valve flotation Interesting times indeed Regards Sp Perhaps some clever clogs might be able to track down what they received for the sale. It could be significant
spurious
23/2/2016
15:15
Wonder what they will use the money for..... Biomerics Divests HTP-Biomerics Medical February 17, 2016 Biomerics LLC, a leading contract manufacturer and innovative polymer solutions provider for the medical device industry, announced today the divestment of its holdings in HTP-Biomerics Medical LLC to its partner HTP-Meds LLC. In a follow-on transaction, HTP-Meds LLC has been sold to Hitachi Metals, a division of Hitachi Corporation with global annual sales of $95 billion USD. The terms of the transaction were not disclosed. HTP-Biomerics Medical LLC, located in Ashaway, RI was a 50/50 joint venture between HTP-Meds LLC and Biomerics LLC of Salt Lake City, UT. Established in 2011, HTP-Biomerics Medical has become a leading supplier of custom extrusions and braided tubing to the medical device industry. “The HTP-Biomerics Medical LLC joint venture has been an excellent business unit for both Biomerics LLC and HTP-Meds LLC,” remarked Travis Sessions, CEO of Biomerics. “Over the years, we have seen tremendous growth and strong partnerships come out of the joint venture. The timing was right to divest this business unit and take the next step in our growth strategy.” With this divestment, Biomerics retains its state-of-the-art facilities in Salt Lake City, UT and Rogers, MN. Biomerics is a full service medical device contract manufacturer that specializes in materials, molding, extrusion, advanced catheters, and assembly of medical devices. Biomerics provides complete development and manufacturing solutions for the cardiovascular, structural heart, cardiac rhythm management, electrophysiology, neurovascular, vascular access, and pain management markets. “We will be investing the proceeds from the sale right back into our business in an effort to expand our capabilities and offerings for our customers,” added Mr. Sessions. “We remain focused on our vertical integration strategy that enables us to provide customers with next generation solutions quickly and cost effectively. We are excited about the sale and the many opportunities that it will bring to the business.” About Biomerics Biomerics LLC specializes in the design, development, and production of finished medical devices used in diagnostic and interventional procedures. Biomerics provides complete development and manufacturing solutions for customers in the cardiovascular, structural heart, cardiac rhythm management, electrophysiology, neurovascular, vascular access, and pain management markets. Headquartered in Salt Lake City, Biomerics has operations across three ISO-13485 compliant facilities.
gac141
17/2/2016
15:24
Hoorah Good days return And May
bbr391
15/2/2016
19:57
If only George. Try talking to Meldex or Globo shareholders who have seen their Directors shaft them big time. As I said ages ago, the chances of a quick solution is probably zero.
cocker
13/2/2016
13:00
No point having a website when ultimately the just will prevail and there will be those like me who will do all they can...... And He Knows it! Sleep well.... Remember Life is like a Boomerang what you give YOU GET BACK! ....Karma...
gac141
13/2/2016
12:52
If they do it must be in the dark web.
tadders2
12/2/2016
16:41
Spurious , Either scenario is possible .Like you I am in the dark as to what next ? Weird trading at 26.5p though . I can see good value here at these prices . That of course is why you should invest in any company . It all remains highly interesting what comes next . The plot is thicker than a bodmin mist . I am of course on the positive side that Eddie will treat us fairly . Good luck All And Mat
bbr391
12/2/2016
12:45
Foldax Fund Raising History Form D Fundraising History Investment Overview Filing History Foldax, Inc. has filed 5 Form Ds since 2008. Of these filings, 4 have been for unique offerings. Through these filings, they have raised $3,050,000, and reported $0 remaining. They have not paid finder's fees or sales commissions in connection with these offerings. They have not used any of the proceeds from its offerings to pay officers or directors. The types of securities they have issued are Equity, Debt, and other securities. They have relied on the following exemptions in past filings Rule 506(b). Analysis of Past Filings Foldax, Inc. has filed 4 more filings compared to an average company in the Other category. They have had 3 more unique offerings compared to an average company in the Other category. The total amount raised they have raised is 408% higher than the average for a company in the Other category. They apparently have 7 investors over 5 fundraisings
gac141
12/2/2016
10:46
http://form-d.findthecompany.com/l/160932/Foldax-Inc Hi Harrogate Hope this helps also Regards Patrick
spurious
12/2/2016
09:47
http://www.octafinance.com/foldax-2-50-million-financing-sean-brady-published-sep-8-form-d/
gac141
12/2/2016
08:13
SP - all interesting stuff. I have been watching Foldax and couldn't see that they had raised $2m recently - have you got a link. I would have thought they might have missed the boat with the biotech bubble now burst for silly valuations. Love your scenario though !!
harrogate
11/2/2016
21:16
bbr I originally felt that the £2million (just over 3 million dollars) was raised to cover the pending court case and any potential damages.The way it was raised meant the Co did not need to disclose the reason for it convenient as I wouldnt think any would be investors would be happy risking their capital on potential future damages. I was also most surprised at how quickly this sum was raised by Foldax after seemingly struggling to raise a far smaller amount as start up capital. It makes me think they must have been working very closely with a friendly investor who was persuaded by Maguires strategy. The interesting question is what might MaGuires strategy be He could hope that he wins the court case and/ or Aor runs out of money I think both these scenarios are unlikely He could on the other hand go on the front foot and make a knockout bid for Elasteon conditional on Aor dropping the court case while retaining the valuable heart valve. It would appear Foldax might have a backer with deep pockets and they would need to pay a hefty premium for the current Aortech BOD to give them houseroom. However despite the obvious bad feeling between the parties this could be a deal that suits both and ultimately Aor shareholders would benefit Aor could sell Elasteon for a premium say up to £10 million (bearing in mind loss of potential damages of £2mill) and be free to float the heart valve project from a position of real strength. Maguires options would appear more limited but buying Elasteon would offer Foldax an out from a poential terminal situation freeing it from future litigation and allowing it a chance to develop its business. All this is guess work and assumes Aortech has the stronger legal case which I am convinced given time it will win but Foldax raised money for a reason and time is not on their side. Perhaps there is a deal to be done from a position of overwhelming strength in the interests of Aortech shareholders despite the understandable animosity The recent share volume would suggest something is going on but there are 2 parties that need to reach a settlement so could a deal be on the cards Your guess is as good as mine regards SP
spurious
11/2/2016
17:20
But who sold 5% of the company ?
harrogate
Chat Pages: 132  131  130  129  128  127  126  125  124  123  122  121  Older


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20160504 07:56:12